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Context: Dietary fibers have been associated with a reduced incidence of type 2 diabetes mellitus
in epidemiological studies; however, the precise mechanisms are unknown.
Objective: The objective of the studywas to evaluate the efficacy and site of action of an insoluble
dietary fiber derived frommaize (HAM-RS2) in improving insulin resistance in subjects at increased
risk of type 2 diabetes mellitus.
Design: This study was a randomized, controlled crossover, dietary intervention study.
Setting: The study was conducted at the Centre for Diabetes, Endocrinology, and Research, Royal
Surrey County Hospital, Guildford, United Kingdom.
Participants: Fifteen men and women with insulin resistance participated in the study.
Intervention: The intervention included 40 g/d HAM-RS2 compared with amatched placebo for
8 wk.
Main Outcome Measures: After each supplement, participants underwent a two-step hyperinsu-
linemic-euglycemic clamp study with the addition of glucose tracers; a meal tolerance test; arte-
riovenous sampling across forearm muscle tissue; and a sc adipose tissue biopsy for assessment of
gene expression.
Results: There was enhanced uptake of glucose into the forearm muscle measured by arterio-
venous sampling (65 15% increase after resistant starch; P 0.001). Adipose tissue functionwas
also affected, with enhanced fatty acid suppression after HAM-RS2 treatment and an increase in
gene expression for hormone sensitive lipase (P  0.005), perilipin (P  0.011), lipoprotein lipase
(P 0.014), and adipose triglyceride lipase (P 0.03) in biopsy samples. Therewas no effect on the
insulin sensitivity of hepatic glucose production or plasma lipids after HAM-RS2.
Conclusion: HAM-RS2 improved peripheral but not hepatic insulin resistance and requires further
study as an intervention in patients with or at risk for type 2 diabetes. (J Clin Endocrinol Metab 97:
3326–3332, 2012)
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In the United Kingdom, it is estimated that 10% of theNational Health Service budget is spent in the treat-
ment of type 2 diabetes mellitus (T2DM), currently es-
timated at £1.3 billion (source: Diabetes UK, February
2010), whereas in the United States, the estimated
amount spent is $119.2 billion, again 10% of all health
care costs (1).
A clear priority for diabetes in terms of both public
health and economics therefore involves preventing the
development of new cases of T2DM, against a back-
ground of increased levels of obesity. Lifestyle interven-
tion should play a major part of diabetes prevention and
remain a constant theme throughout management.
Maintenance of an appropriate body weight is impor-
tant because 80%of all patients with T2DMare classified
as obese (2); however, weight loss is notoriously difficult
to achieve and maintain. It is not only the quantity of the
diet but also the quality that may also provide a solution;
high fiber intake and a reduction in trans-fatty acids and
saturated fats have all been linked to increases in tissue
insulin sensitivity (3), a critical target in diabetes preven-
tion. InWesternized countries, especially theUnited States
and the United Kingdom, the intake of dietary fibers and
whole grains are particularly low (4), falling well short of
modest government targets. There is evidence that filling
the fiber gap may make a difference.
Dietary fibers can be classified as either viscous or non-
viscous.Viscous fibers causeawell-documentedreduction in
the rate of glucose absorptionwith reductionof the glycemic
response (5). Nonviscous fibers such as resistant starch (RS)
have no direct effect on glucose absorption from the gut yet
have been shown in short-term human studies to enhance
whole-body insulin sensitivity (6–8). Epidemiological and
mechanistic evidence also suggests insoluble fibers are
linked to a reduced incidence of T2DM (9). Many fibers
currently available, such as RS, are now being reclassified
as functional foods, offeringhealthbenefits beyond simple
nutrition. Using a supplement approach, we have previ-
ously determined the metabolic effects of a granular form
of type 2 RS, derived from high-amylose maize (HAM-
RS2) in healthy subjects.HAM-RS2 increaseswhole-body
insulin sensitivity and significantly reduces adipose tissue
lipolysis, findings that could be clinically important for
both diabetes care and prevention (reviewed in Ref. 10).
The concept that some dietary fibers change peripheral
metabolismas a result of changes in short-chain fatty acids
originating from colonic fermentation and thus serve as a
signal between adipose tissue andmuscle are supported by
our original work (6), but it is unknown how far these
finding go in terms of diabetes prevention. The lack of
appropriate intervention human data has been recently
highlighted (11). Using an integrated whole-body ap-
proach, using stable-isotope tracers for the first time to
differentiate between changes in hepatic glucose produc-
tion and peripheral glucose uptake, we have investigated
the metabolic potential of HAM-RS2 in obese, insulin-
resistant individuals, a key target group in the prevention
of overt T2DM.
Research Design and Methods
All aspects of the studywere conducted in accordancewith the
Declaration of Helsinki and received a favorable ethical opin-
ion from the East Kent Research Ethics Committee and the
University of Surrey Ethics Committee. This trial was regis-
tered via the International Standard Randomised Controlled
Trial Number reference number 56997186. All participants
gave written informed consent.
Research participants
Sixteen (eight female) healthy subjects with insulin resistance
as defined by the European Group for the Study of Insulin Re-
sistance criteria but without a diagnosis of T2DM were re-
cruited. Fifteen (seven female) subjects completed thewhole pro-
tocol. These diagnostic criteria were chosen as the most
discriminating for the presence of insulin resistance (12). Their
ages ranged from 25 to 70 yr (mean 48.9  3.9 y) with a mean
body mass index of 33.8 1.9 kg/m2 and with a fasting insulin
in the range 60–156 pmol/liter. Subjects all exhibited abdominal
adiposity (meanwaist circumference 1065.1 cm). Participants
were excluded if theyhadahistoryof gastrointestinal, endocrine,
or cardiovascular disease, and none were currently taking any
prescribed medication (with the exception of the contraceptive
pill). Female participants were recruited as being either post-
menopausal or, if premenopausal, studiedwhile taking oral con-
traceptives to avoid potential effects of hormonal fluctuation.
Habitual diet was assessed by the use of 7-d food records and
analyzed using the WinDiets Professional Version program
(Robert Gordon University, Aberdeen, UK).
General protocol
This was a single-blind, crossover dietary intervention com-
paring HAM-RS2 with placebo. Each starch supplement was
consumed daily for 8 wk with an 8-wk washout between treat-
ments. At the end of each supplement, participants underwent
the following: 1) a two-step hyperinsulinemic clamp with the
addition of stable isotopes to differentiate between peripheral
and hepatic insulin sensitivity, 2) a meal tolerance test (MTT)
combined with arteriovenous sampling across forearm muscle,
and 3) a sc adipose tissue biopsy for gene analysis.
Participants avoided strenuous exercise and alcohol for 48 h
preceding each treatment day and were provided with a stan-
dardized low-fat/low-fiber evening meal before each study to
reduce variability. All participants were recruited as being sed-
entary (less than three exercise bouts per week) and instructed to
maintain normal daily activity levels.
The participants were initially randomized to receive either
Hi-maize 260 (Ingredion Inc., Bridgewater, NJ) at 67 g/d ([40 g
RS and 27 g rapidly digestible starch (RDS)] or Amioca (Ingre-
dion Inc.) at 27 g/d (0 gRS and 27 gRDS) for 8wk added to their
habitual diet, separated by an 8-wk washout period. For clarity
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of the presentation inResults andDiscussion, the Hi-maize sup-
plement will be referred to as HAM-RS2 and the Amioca as
placebo. The starches were assayed using a modified version of
the Englyst RS method to determine RS and RDS content (13)
and were supplied as powder in ready-to-use sachets to mix in
with food/drink. Bowel habit and symptom diaries were com-
pleted during each intervention to assess tolerance, and diet di-
aries were completed to assess any changes to background in-
take. Fasting breath hydrogen (Gastrolyzer; Bedfont Scientific,
Maidstone, UK) measurements were taken before each clinical
intervention as a proxy compliance measure.
Metabolic investigations
Euglycemic-hyperinsulinemic clampwith infusion of
[6,6-2H2]glucose
After cannulation and after an initial blood sample a primed
continuous infusion of [6,6-2H2]glucose (170 mg; 1.7 mg/min)
was commenced. Once a steady state of enrichment with the
stable isotopeswas achieved, a further five baseline sampleswere
taken between 100 and 120min for measurement of the glucose
enrichment, glucose, insulin, and nonesterified fatty acid
(NEFA) concentration.At 120min a two-step hyperinsulinemic-
euglycemic clamp was initiated. Step 1 consisted of an insulin
infusion at 0.3mU/kg1  min1 (Acrapid, lowdose;NovoNor-
disk, Copenhagen, Denmark) for 120min tomeasure the insulin
sensitivity of endogenous glucose production (EGP), which is
predominantly a measure of hepatic glucose production, and
lipolysis. Step 2 consisted of an insulin infusion at 1.5 mU/
kg1  min1 (high dose) for a further 180 min to measure the
insulin sensitivity of glucose uptake. Plasma glucose concentra-
tion was maintained at fasting levels using a variable infusion of
20% dextrose spiked with [6,6-2H2]glucose (8 mg/g for step 1
and 10 mg/g for step 2). Blood samples were taken every 10 min
withbloodglucosemeasured immediatelyby the glucoseoxidase
method using a Clandon Scientific analyzer (Yellow Springs In-
struments, Yellow Springs,OH).Additional blood sampleswere
taken between 210 and 240 min and between 390 and 420 min
for glucose andNEFA, representing the two steady-state periods.
Meal tolerance test with tissue with tissue-specific
arteriovenous sampling
To assess the metabolism of skeletal muscle in vivo, we
measured arteriovenous differences across forearm tissue. Se-
rial blood samples were taken from subjects in the fasting state
and for 5 h after a liquid MTT (1804 KJ; 60 g carbohydrate,
12.6 g fat).
Arterialized blood was obtained from a vein draining a hand
placed in heated box (55 C). Venous blood from muscle was
taken from a vein draining the deep tissues of the contralateral
forearm (14). To prevent contamination of the blood from the
forearm vein with blood from the hand, venous blood flow from
the hand was occluded using a wrist cuff inflated to 20 mm Hg
above systolic blood pressure for 2 min before the samples were
taken. Oxygen saturation was used to assess the correct posi-
tioning/arterialization. A cutoff of oxygen partial pressure less
than 65% and oxygen partial pressure greater than 95% were
used for the deep-vein and arterialized samples, respectively.
Simultaneous sampling from the two sites began at 0900 h
after a 12-h overnight fast. Subjects then ingested the liquid test
meal, and further blood samples were taken for 5 h. Forearm
muscle blood flow was assessed by venous occlusion strain-
gauge plethysmography following each blood sample.
Adipose tissue biopsy
An adipose tissue biopsy was performed under local anesthe-
sia (2% lidocaine) 5.5 h after the meal in 10 of 15 subjects. An
open biopsywas taken from the upper buttock region,which has
previously been shown to exhibit metabolic activity (15). Sam-
ples were cleaned and snap frozen in liquid nitrogen and stored
at80C for laterRNAquantification.TotalRNAwasprepared
from the frozen tissue using a commercial kit (Ambion, Austin,
TX). RNA integrity (28S to 18S ratio) was determined with the
Agilent 2100 bioanalyzer and RNA 6000 labChip kit (Agilent
Technologies,Massy, France). RNApreparationswere stored at
80 C until real-time quantitative PCR assays.
Biochemistry
Plasma, triacylglycerol (TG), NEFA, and total cholesterol
were measured enzymatically using a Cobas Mira (Roche Lab-
oratories, Antrim, Northern Ireland). Metabolites from the pla-
cebo and HAM-RS2 arms of the trial were analyzed together
with an intraassay variation less than 2.5% for all metabolites.
Concentration of insulin, total ghrelin, leptin, and adiponectin
were measured by RIA using commercially available kits (Mil-
lipore, Billerica,MA), with an interassay coefficient of variation
of less than 5% for all hormones. Blood for total ghrelin analysis
was first collected into potassium-EDTA containing 200 Kal-
likrein-inhibiting units aprotinin per milliliter blood (Sigma Al-
drich, Poole UK).
Plasma levels of IL-6 and TNFwere measured using com-
mercially available ELISA kits (Gen-Probe Diaclone, Bescan-
c¸on, France), with intra- and interassay coefficients of varia-
tion of less than 4.2% and less than 9%, respectively.
The isotopic enrichment of plasma glucose was measured by
gas chromatography-mass spectrometry on an HP 5971A mass
selective detector (Agilent, Santa Clara, CA). The enrichment
wasdeterminedusingapenta-O-trimethylsilyl-D-glucose-O-me-
thoxime derivative analyzed by selected ion monitoring of the
ions at a charge to mass ratio of 319 and 321 (16). Glucose
concentration of the same plasma sample was determined by a
glucose oxidase method using a Clandon Scientific glucose an-
alyzer (Yellow Springs Instruments).
Quantification of mRNA
Concentration of the mRNA corresponding to the genes of
interest were measured by RT-PCR with a Rotorgene Q
(QIAGEN, Courtaboeuf, France). Primer sequences are available
upon request (hubert.vidal@univ-lyon1.fr). First-strand cDNA
were first synthesized from 250 ng of total RNA in the presence
of100Uof Superscript II (Invitrogen,Eragny, France) usingboth
random hexamers and oligo (deoxythymidine) primers. The
real-time PCR was performed in a final volume of 20 l con-
taining 5 l of a 60-fold dilution of the reverse transcription
reaction medium and 15 l of reaction buffer from the ABsolute
QPCR SYBR Green Mix (Thermo Scientific, Swedesboro, NJ).
For quantification, a standard curve was systematically gener-
ated with six different amounts (150–30,000molecules/tube) of
purified target cDNA cloned in the pGEM plasma (Promega,
Charbonnie`res, France). Each assaywas performed in duplicate.
Data were normalized using hypoxanthine phosphoribosyl
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transferase 1mRNA levelsmeasured in each sample by real-time
PCR as an internal standard (17).
Calculations
Fasting insulin sensitivity and-cell functionwere assessedby
homeostatic model assessment (HOMA) (18).
During the MTT, arteriovenous differences in metabolite
concentrations were calculated. Absolute flux was calculated as
the product of the arteriovenous concentration difference and
tissue blood/plasma flow as appropriate. Total fatty acid uptake
into muscle was calculated from the rate of TG and NEFA re-
moval across the tissue as previously described (6). Glucose
clearance was calculated as the total glucose flux/insulin area
under the curve.During the two-step clamp, theEGPandglucose
disposal rate (Rd) were calculated, using the model proposed by
Steele (19) modified for the inclusion of stable isotopes. The
volume of distribution was assumed to be 22% of body weight.
The calculation was also modified for inclusion of [6,6-
2H2]glucose in the dextrose infusion (20). Before calculation of
glucose turnover, plasma glucose concentration and glucose en-
richment time courses were smoothed, using optimal segments
technique analysis (21). For each time point, the mean EGP and
Rd were calculated. Data are expressed as the mean EGP and Rd
from five sample values taken during a steady state.
Statistical analysis
Resultsarepresentedasmean SEM.All statisticalanalyseswere
carried out using SPSS version 16 (SPSS Inc. Chicago, IL). End-of-
treatment effects were compared between HAM-RS2 and placebo
in a crossover design. Time-course datawere analyzed by repeated-
measuresANOVA. Summarydatawere analyzedusingpaired Stu-
dent’s t testswhennormallydistributedorthenonparametricequiv-
alent, theWilcoxon signed rank test.Values ofP0.05were taken
as significant.
Results
The inclusion of an additional 40 g/dHAM-RS2 into the
habitual diet of participants was well tolerated [mean
total fiber intake increased from 20 g/d (range 11.3–
29.6 g/d) to 58 g/d]. There was a significant effect of
HAM-RS2 intake on fasting breath hydrogen [27  5
vs. 8  2 ppm (P  0.001)]. There was no significant
effect of this increase in fiber intake on stool frequency,
abdominal pain, flatulence, or bloating as determined
by daily bowel habit and symptom diaries. Mean daily
macronutrient intake from 7-d diet diaries did not differ
between treatment regimens (placebo: 233 g carbohy-
drate, 76.4 g fat, and 8.5 MJ/d; HAM-RS2: 238 g car-
bohydrate, 76.9 g fat, and 8.7 MJ/d), and there was no
subsequent change in body weight (Table 1).
Glucose metabolism and insulin sensitivity
There was a significant decrease in both the fasting
glucose (P  0.017) and insulin (P  0.041) concentra-
tions after HAM-RS2 treatment (Table 1) and conse-
quently a decrease in the calculated HOMA for insulin
resistance,with amean10.47.5% improvement in fast-
ing insulin resistance compared with placebo condition
(P  0.029).
During the two-step euglycemic-hyperinsulinemic
clamp, no difference was observed in the basal EGP be-
tween treatments (placebo: 8.5 0.6mol/kg1  min1;
HAM-RS2: 8.4  0.6 mol/kg1  min1) or after low-
dose insulin (placebo: 5.3  0.6 mol/kg1  min1;
HAM-RS2: 4.7 0.7 mol/kg1  min1). There was an
increase in the peripheral glucose uptake (Rd) after high-
dose insulin infusion (placebo: 40.5  3.5 mol/
kg1  min1;HAM-RS2: 47.1 4.1mol/kg1  min1,
a mean 21.1  9.0% difference between treatments; P 
0.031) despite no significant difference in the prevailing
insulin concentration during the infusion (Fig. 1).
During the MTT with arteriovenous sampling across
forearm tissue, there was a significant increase in glucose
uptake after theHAM-RS2 treatment (Fig. 2), with a 65
15% increase in total glucose flux (P  0.001).
Fat metabolism
Therewas no effect ofHAM-RS2 consumption on fast-
ing/postprandial TG or total cholesterol concentrations.
Before the clamp, fasting NEFA levels were lower at base-
line and suppression of plasma NEFA by insulin was en-
hanced after HAM-RS2 treatment (P 0.041) compared
with placebo (Fig. 1). During the MTT, the net uptake of
TABLE 1. Anthropometric and fasting plasma
measurements taken after 8 wk of supplementation
with either 40 g/d HAM-RS2 compared with placebo
Placebo HAM-RS2 P
Body weight (kg) 99.1 (7.7) 99.1 (7.3) NS
Body mass index (kg/m2) 33.8 (2.0) 33.9 (1.9) NS
Fat mass (kg)a 37.6 (4.0) 37.7 (3.5) NS
Fat-free mass (kg)a 61.5 (5.0) 61.5 (4.9) NS
Systolic blood pressure
(mm Hg)b
126 (5.2) 125 (4.2) NS
HOMA-%B 182.5 (12.6) 175.9 (11.9) NS
HOMA-IR 2.9 (0.2) 2.5 (0.2) 0.029
Fasting glucose (mmol/liter) 5.2 (0.11) 5.0 (0.1) 0.017
Fasting insulin (pmol/liter) 129 (10.2) 108 (8.4) 0.041
Fasting leptin (ng/ml) 19.0 (2.2) 20.3 (2.2) NS
Fasting adiponectin (ng/ml) 8120 (148) 7720 (158) NS
Fasting total cholesterol
(mmol/liter)
4.3 (0.3) 4.2 (0.4) NS
Fasting TG (mmol/liter) 1.2 (0.1) 1.4 (0.2) NS
All values are presented mean (SEM), n  15. All measurements were
taken in the morning after an overnight fat. Comparisons were made
with a Wilcoxon signed-ranks test. HOMA-%B, -Cell function;
HOMA-IR, HOMA for insulin resistance (17); NS, not significant.
a Measured using foot-to-hand bioimpedance (Tanita TBF-300,
Amsterdam, The Netherlands).
b Mean of three readings taken with the subject in the sitting position
(Omron MX3 Plus, Omron Healthcare, Milton Keynes, UK).
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fatty acids into skeletalmuscle reflects fatty acids fromtwo
sources: those derived from lipoprotein lipase (LPL) lipol-
ysis of TG and those taken up as NEFA from the circula-
tion. The overall uptake of fatty acids into skeletal muscle
was increased, approaching significance (16%, P 
0.055) after HAM-RS2. However, the relative contribu-
tions of fatty acids did change significantly. HAM-RS2
decreased uptake of fatty acids as NEFA (20%, P 
0.046) and increased TG lipolysis (24%, P  0.028).
Hormones and inflammatory markers
There was no significant difference in fasting leptin or
adiponectin levels between treatments and no effect on
either fasting or postprandial suppression of plasma total
ghrelin (data not shown). Despite the participants in this
dietary intervention having both insulin resistance and ab-
dominal obesity, the inflammatory markers IL-6 and
TNF were below the limit of detection in 14 of 15 sub-
jects using commercially available assays.
Adipose tissue gene expression
To supplement the physiological findings of the effects of
HAM-RS2 on adipose tissue lipolysis, the expression of key
genes were measured in sc adipose biop-
sies (Table 2). There was enhanced ex-
pressionof several genes involved in fatty
acid metabolism including LPL, adipose
triglyceride lipase (ATGL), perilipin, adi-
ponectin, and hormone-sensitive lipase
(HSL), in all cases representing at least a
2.0-fold increase in tissue expression.
There was no effect of HAM-RS2 con-
sumption on the expression of either vis-
fatin or peroxisomal proliferator-acti-
vated receptor (PPAR)-.
Discussion
In this study we have built on our own published data and
that of others on the potent metabolic potential of a dietary
fiber derived from cereal, in healthy individuals, and trans-
lated this into the potential treatment of insulin resistance (6,
8, 22) in those with an elevated risk of T2DM. In addition,
we have demonstrated for the first time changes at the tran-
scriptional level in sc adipose tissue and that the potential
mechanism linking HAM-RS2 to increased insulin sensitiv-
ity involves peripheral metabolism (adipose and muscle)
without any change in hepatic glucose handling. This is an
important finding in determining the site of action of dietary
fiber in modulating insulin sensitivity, especially for the de-
sign of complementary drug/lifestyle treatments.
Adipose tissue expression of LPL, HSL, and ATGL, en-
zymes involved in lipid uptake and mobilization, are typi-
cally reduced in both obesity andT2DM(23) (24), with low
HSLexpressionconstitutingapossibleprimarydefect inobe-
sity. In this study there was a clear stimulatory effect on the
expressionofadipose tissue (AT)LPL,ATGL,andHSLafter
fiber intake.An increases inbothHSLandLPLmRNAinAT
(25)may indicate increased adipocyte differentiationwithin
the tissue (26). A failure of AT to differentiate may be the
critical step thatmarks the transition fromobesity toT2DM.
FIG. 1. Plasma Insulin (A) and NEFA (B) during the two-step hyperinsulinemic-euglycemic
clamp. There was no difference in the insulin concentration between treatments, placebo
(open circles) vs. HAM-RS2 (closed circles). After HAM-RS2 treatment, there was significant
treatment effect (open circle; repeated measures ANOVA, P  0.041), compared with
placebo treatment (closed circle). Data are means  SEM.
FIG. 2. Glucose flux into muscle tissue measured with arteriovenous
sampling across the forearm and venous-occlusion strain gauge
plethysmography. There was a significant increase in glucose uptake
after HAM-RS2 treatment (closed circles) compared with placebo
treatment (open circles) (P  0.001). Data are means  SEM.
TABLE 2. Gene expression in sc adipose tissue biopsies
taken after 8 wk supplementation with 40 g/d HAM-RS2
compared with placebo
Placebo HAM-RS2 P
LPL 96.2 (19.8) 261.0 (52.3) 0.014
ATGL 48.3 (4.9) 82.7 (12.7) 0.03
Visfatin 5.3 (0.5) 5.3 (0.7) NS
Perilipin 294.0 (40.5) 570.7 (76.6) 0.011
Adiponectin 146.9 (14.9) 250.2 (45.4) 0.053
HSL 33.2 (4.5) 61.3 (6.0) 0.005
PPAR- 8.1 (0.9) 9.2 (2.0) NS
Data are expressed as mean (SEM), n  10. Values are as arbitrary units
relative to the constitutively expressed housekeeping gene HPRT.
Comparisons were made using the Wilcoxon signed-ranks test.
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HAM-RS2doesnot seemto impactonobesityper sebecause
theobservedchangesoccurwithoutaneffectonbodyweight
but would appear to affect the function of the existing AT.
This would appear to demonstrate that tissue insulin sensi-
tivity is increased due to a change in the physiological func-
tion of AT with the effects observed similar to those found
with pharmacological diabetes treatment.
Colonic fermentationofHAM-RS2 increases plasma lev-
els of the short-chain fatty acids acetate and propionate (6),
which are taken up into AT and skeletal muscle tissue. Both
acetate and propionate are highly bioactive and could ex-
plain most, if not all, of the improvements in insulin sensi-
tivity found with HAM-RS2. This study also demonstrated
a decrease in circulating NEFA after HAM-RS2, suggesting
an improvement in the suppression of lipolysis with insulin.
Interestingly, after HAM-RS2, we also found increased tis-
sue expression of perilipin, whichmay be themolecular me-
diator of this observed antilipolytic effect (27). HAM-RS2
may mimic the effects of drug treatment by acting on the
samemolecularpathways; for example, propionatehasbeen
reported topotentiallyactas ligandforPPAR.Wefoundno
increase in the expression of PPAR in AT but cannot ex-
clude an effect on actual activity, as supported by increased
expression of LPL and adiponectin, two well-known target
genes of PPAR and thiazolidinediones in human adipose
tissue(28,29).HAM-RS2wouldthereforeappeartoexert its
beneficial effect on insulin sensitivity primarily in the periph-
ery (adipose and muscle) rather than by reducing hepatic
glucose production. Importantly, the effects are also inde-
pendent from any change in either macronutrient/energy in-
take or body weight.
Consistently, dietary HAM-RS2 shows no effect on
plasma TG or cholesterol (30). The most important clinical
effect seen with HAM-RS2, namely the increased uptake of
glucose into skeletalmuscle,we propose as secondary to pri-
mary changes in AT function. The increase in postprandial
glucose uptake using arteriovenous sampling directly across
skeletalmuscle showedadramatic improvement (65%), in
excess of what has been reported with drug treatments (29)
using a similar sample size and methodology. Interestingly,
there was also enhanced uptake of fatty acids by skeletal
muscle that might, in normal circumstances, be expected to
lead to increased intramyocellular TG storage and a reduc-
tion in insulin sensitivity. The reverse is in fact true: despite
increased fatty acid uptake, muscle TG storage when mea-
sured by magnetic resonance imaging is reduced by HAM-
RS2 (8).
An important aspect of this study is that the metabolic
benefit achieved; a mean 65% increase in postprandial glu-
cose disposal and a 10% reduction in fasting insulin resis-
tance (HOMA)was independent fromanychange in lifestyle
or body weight. Recent work has demonstrated the benefi-
cial effects of extreme energy restriction (2.5 MJ/d) on met-
abolic control in T2DM (31). In this 8-wk nonrandomized
intervention, a mean 15 kg loss in body weight resulted in
significantdecrease inEGPbutnoeffectonperipheral insulin
sensitivity, which directly opposes the results found with
HAM-RS2 (using identical methodology). Weight loss has
been shown to reduce intrahepatic TG (32), so an improve-
ment in EGP is as expected; however, the lack of an effect on
muscle insulin sensitivitywithweight loss demonstrates that
energy restriction alone cannot restore the metabolic milieu
in those with insulin resistance/T2DM and nutrient quality
may also be critical.Weight loss combinedwith a high-fiber
intakemay thenbeexpected tohavecomplementarybenefits
for glucosemetabolism (addressingbothhepatic andperiph-
eral insulin resistance simultaneously), althoughthis remains
to be tested.
Another proposed mechanism linking fiber intake specifi-
cally to insulin sensitivity relates tomodifying systemic inflam-
mation via changes in both gut microbiota and intestinal per-
meability (33). HAM-RS2 has indeed been demonstrated to
havemild prebiotic effects (34), although in this study levels of
inflammatorymarkerswere below the level of detection for 14
of 15 participants, indicating that any improvement in insulin
sensitivitywasnotsecondarytoachangeininflammatorystatus
in this group. This is in line with other human fiber feeding
studies ((8, 22).
A limitation of this crossover study is the small sample
size; however, in contrast, a strength is that we have manip-
ulated only one component of the diet. Larger randomized
controlled feeding studies manipulating only fiber intake,
withfewerdetailedmeasurements,wouldberequirednowto
add to the evidence for HAM-RS2 in the prevention of dia-
betes. In this study we have demonstrated the efficacy of
dietary HAM-RS2 in the improvement tissue insulin resis-
tance in a small cohort, by increasing peripheral glucose up-
take, through a cascade thatmay originate in adipose tissue,
although the exact molecular mechanism warrants further
investigation. The next logical step is to assess the role of
HAM-RS2 for the first time as a potential therapeutic treat-
ment for patients with T2DM.
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